Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI
PRECLUDE-MI
1 other identifier
observational
100,000
0 countries
N/A
Brief Summary
Recurrent myocardial infarctions (reinfarctions) can be due to recurrence at the original treatment site, the presence of untreated lesions elsewhere, or in progressive lesions. There are scarce published data describing the localization (affected vessel/s) and severity (NSTE-ACS/STE-ACS) of reinfarction(s) compared to the index MI (e.g proportion of recurrent infarctions in the previously diseased vessel) in large unselected patient populations. If reinfarctions are generally more severe than index MI/recurrent MI(s), this might have implications for choice of treatment and treatment length. Moreover, data from unselected patient populations on the overall incidence pattern/rate of patients experiencing multiple reinfarctions is sparse. Patients who experience multiple ischemic events may be a subset of patients who are poor responders to therapy. There is also a possibility that patients with multiple events are less likely to have received evidence-based therapy such as coronary stenting, novel and more effective antithrombotics and modern lipid lowering treatment for the initial event. Poor adherence to secondary prevention measures (e.g. low compliance to medication and adherence to cardiac rehabilitation programs) may also increase the risk of recurrent events. Therefore identification of the baseline characteristics, including treatment decision strategies in the setting of a myocardial infarction, among such subjects may allow modifications of the clinical management strategy prior to the occurrence of subsequent ischemic events. Such modifications could include providing a more intensive or additional therapy in certain patient groups or find strategies to improve patient adherence and drug compliance. A patient with reinfarctions requires more hospitalizations, treatments, laboratory tests, and out-patient visits, resulting in overall increased costs. From the patient perspective, recurrent events result in higher mortality and worsened quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 28, 2017
CompletedFirst Posted
Study publicly available on registry
April 4, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2017
CompletedApril 5, 2017
April 1, 2017
2.3 years
March 28, 2017
April 3, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pattern of repeat cardiovascular events during follow-up after first diagnosed event-MI.
max 8 years follow-up
Study Arms (1)
No re-MI, one re-MI, > one re-MI
From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or \> re-MI will be described.
Eligibility Criteria
Patients registered in SWEDHEART with an index-MI within the observation period.
You may qualify if:
- Patients registered in SWEDHEART with an index-MI within the observation period
You may not qualify if:
- Less than one year follow-up data
- Previous MI
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Uppsala Universitylead
- AstraZenecacollaborator
Related Publications (1)
Varenhorst C, Hasvold P, Johansson S, Janzon M, Albertsson P, Leosdottir M, Hambraeus K, James S, Jernberg T, Svennblad B, Lagerqvist B. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018 Jan 9;7(1):e007174. doi: 10.1161/JAHA.117.007174. Epub 2018 Jan 4.
PMID: 31913732DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 8 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2017
First Posted
April 4, 2017
Study Start
June 1, 2015
Primary Completion
October 1, 2017
Study Completion
October 1, 2017
Last Updated
April 5, 2017
Record last verified: 2017-04
Data Sharing
- IPD Sharing
- Will not share